<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434576</url>
  </required_header>
  <id_info>
    <org_study_id>HGS1025-C1106</org_study_id>
    <nct_id>NCT01434576</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis</brief_title>
  <official_title>A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics and Safety of HGS1025, a Human Monoclonal Anti-CCR5 Antibody, in Subjects With Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Human Genome Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Human Genome Sciences Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacodynamics, safety, and pharmacokinetics
      of HGS1025 in patients with moderate to severe ulcerative colitis.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor withdrew study for business reasons
  </why_stopped>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics (serum &amp; tissue biological markers; CCR5 receptor occupancy)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in CCR5 properties; change in inflammatory markers in blood and colon.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Decrease in Mayo Score and rectal bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type, frequency, and severity of adverse events</measure>
    <time_frame>Through 8 weeks after the last dose of study agent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>4 weeks</time_frame>
    <description>Decrease in Mayo Score and rectal bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission</measure>
    <time_frame>4 weeks &amp; 8 weeks</time_frame>
    <description>Decrease in Mayo Score and no rectal bleeding or colon friability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucosal healing</measure>
    <time_frame>4 weeks &amp; 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>HGS1025 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HGS1025 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HGS1025</intervention_name>
    <description>2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response</description>
    <arm_group_label>HGS1025 2 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HGS1025</intervention_name>
    <description>10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response</description>
    <arm_group_label>HGS1025 10 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults at least 18 years of age

          -  Active, moderate to severe ulcerative colitis (UC) confirmed by endoscopy

          -  Currently on 1 or more of the following UC treatment medications: 5-aminosalicylates
             (5-ASA), corticosteroids, azathioprine, 6-mercaptopurine (6MP), and/or other
             immunosuppressive or immunomodulatory agents including cyclosporine, tacrolimus,
             methotrexate, and mycophenolic acid

          -  Not pregnant or nursing

          -  Females of non-childbearing potential or females of childbearing potential must be
             willing to practice abstinence from intercourse from 2 weeks prior to first dose of
             study agent and for 8 weeks after the last dose of study agent or use effective
             contraception for 1 month prior to the 1st dose of study agent and through 8 weeks
             after the last dose of study agent

          -  Males must agree to use effective contraception throughout the study and for 8 weeks
             after the last dose of study agent

          -  Have the ability to provide informed consent and comply with study procedures

        Exclusion Criteria:

          -  Received any of the following within 60 days of the first dose of study agent:
             Anti-TNFÎ± therapy; integrin receptor antagonist; intravenous immunoglobulin; high dose
             prednisone or prednisone equivalent (greater than 60 mg/day); any investigational
             agent including immunosuppressive/immunomodulatory or non-biologic agents

          -  Have had a change in corticosteroid, 5-ASA, or other
             immunosuppressive/immunomodulatory agents within 30 days of Day 0

          -  History of liver disease

          -  History of a major organ transplant

          -  History of prior large bowel resection

          -  Current unstable or uncontrolled acute or chronic diseases not due to UC

          -  History of malignant neoplasm within the last 5 years, except for some types of
             adequately treated cancers of the skin or carcinoma in situ of the uterine cervix

          -  Current or recent drug or alcohol abuse or dependence

          -  History of a positive test for HIV or test positive for Hepatitis B (HBsAg) or
             Hepatitis C

          -  Have a history of severe drug allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2011</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

